

Benralizumab (Fasenra®)

Reduce direct handling to a minimum and wear appropriate personal protective equipment

Form & Storage	Each pre-filled syringe contains 30 mg benralizumab/1mL.	<div style="background-color: #003366; color: white; padding: 5px;">Store in a refrigerator (2°C to 8°C).</div> <div style="padding: 5px;">Fasenra may be kept at room temperature up to 25°C for a maximum of 14 days. After removal from the refrigerator, Fasenra must be used within 14 days or discarded.</div>
Reconstitution	Already in solution Visually inspect Fasenra for particulate matter and discolouration prior to administration. Fasenra is clear to opalescent, colourless to yellow, and may contain translucent or white to off-white particles. Do not use Fasenra if liquid is cloudy, discoloured, or if it contains large particles or foreign particulate matter.	
Compatibility & Stability	This medicinal product must not be mixed with other medicinal products	
Administration	Subcutaneous Injection <ul style="list-style-type: none"> • Prior to administration, warm Fasenra by leaving carton at room temperature. This generally takes 30 minutes • It should be injected into the thigh or abdomen 	
Documentation Requirements	In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded in medical notes	
Adverse Drug Reactions	<ul style="list-style-type: none"> • The most commonly reported adverse reactions during treatment are headache and pharyngitis. • Acute systemic reactions including anaphylactic reactions and hypersensitivity reactions (e.g. urticaria, papular urticaria, rash) have occurred following administration of benralizumab. These reactions may occur within hours of administration, but in some instances have a delayed onset (i.e. days). 	
Additional Information	<p>Fasenra solution for injection is supplied in a sterile single-use pre-filled syringe or pre-filled pen for individual use. Do not shake. Do not freeze.</p> <p>First three injections are usually administered in the Infusion Unit. Follow up injections are at 8 weekly intervals. Patient can return to Asthma out patients for injection or opt to self-administer.</p> <p>See PPG-CUH-CUH-243 <u>Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH</u> for more information</p>	

Information provided relates to Fasenra® (Astra Zeneca)